PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
58.07%
Positive revenue growth while CVE is negative. John Neff might see a notable competitive edge here.
163.75%
Positive gross profit growth while CVE is negative. John Neff would see a clear operational edge over the competitor.
206.96%
Positive EBIT growth while CVE is negative. John Neff might see a substantial edge in operational management.
206.96%
Positive operating income growth while CVE is negative. John Neff might view this as a competitive edge in operations.
23.23%
Net income growth under 50% of CVE's 1329.37%. Michael Burry would suspect the firm is falling well behind a key competitor.
23.20%
EPS growth under 50% of CVE's 1340.00%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
23.41%
Diluted EPS growth under 50% of CVE's 1340.00%. Michael Burry would worry about an eroding competitive position or excessive dilution.
-0.05%
Share reduction while CVE is at 0.57%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
0.23%
Diluted share reduction more than 1.5x CVE's 0.57%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
2.75%
Dividend growth under 50% of CVE's 5.80%. Michael Burry might suspect more pressing needs for cash or weaker earnings power.
52.01%
OCF growth at 75-90% of CVE's 61.79%. Bill Ackman would demand better working capital management or cost discipline.
95.51%
FCF growth under 50% of CVE's 740.91%. Michael Burry would suspect weaker operating efficiencies or heavier capex burdens.
-66.84%
Both companies have negative long-term revenue/share growth. Martin Whitman would question if the entire market or product set is shrinking.
-52.62%
Both face negative 5Y revenue/share CAGR. Martin Whitman would suspect macro headwinds or obsolete product offerings across the niche.
12.06%
Positive 3Y CAGR while CVE is negative. John Neff might view this as a sharp short-term edge or successful pivot strategy.
-61.62%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-70.06%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
-65.27%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
-573.05%
Negative 10Y net income/share CAGR while CVE is at 1507.48%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-278.61%
Negative 5Y net income/share CAGR while CVE is 628.73%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
13.02%
Below 50% of CVE's 465.15%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
-50.44%
Negative equity/share CAGR over 10 years while CVE stands at 0.00%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-66.09%
Negative 5Y equity/share growth while CVE is at 15.58%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
6.58%
Below 50% of CVE's 17.26%. Michael Burry suspects a serious short-term disadvantage in building book value.
-39.24%
Cut dividends over 10 years while CVE stands at 0.00%. Joel Greenblatt suspects a weaker ability to return capital vs. the competitor.
-77.36%
Both lowered dividends mid-term. Martin Whitman might suspect broad sector constraints or strategic shifts from dividends.
-77.37%
Both firms reduced dividends recently. Martin Whitman suspects broader macro or industry issues forcing cost and payout cuts.
-6.13%
Both reduce receivables yoy. Martin Whitman suspects a shift in the entire niche’s credit approach or softer demand.
-69.64%
Both reduce inventory yoy. Martin Whitman suspects a broader move to lean operations or industry slowdown in demand.
-9.18%
Negative asset growth while CVE invests at 6.19%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-14.01%
We have a declining book value while CVE shows 16.63%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
-1.51%
We’re deleveraging while CVE stands at 7.44%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
No Data
No Data available this quarter, please select a different quarter.
-1.04%
We cut SG&A while CVE invests at 2.74%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.